title: [Gingival hypertrophy due to cyclosporine. A clinico-statistical study in 82 patients].
abstract: Eighty-two patients were observed at the Dental Department at Parma University. Seventy-six of them had renal transplant and 6 liver transplant. They were in immunosuppressive therapy with cyclosporina, 42 of them were also in calcium antagonist therapy. Gingival hypertrophy was observed in 52 subjects (63.4%) 25 (30%) patients underwent surgical operation, 6 of them (24%) showed a relapse about 3 months after the first operation. Clinical data were measured in accordance with 5 indicators: the level of oral hygiene, cyclosporinemia, contemporaneous use of calcium antagonist, the duration of therapy and the DMF index. By the results obtained, it's possible to suppose that the gravity of the disease is related to the contemporaneous use of calcioantagonist, but it wasn't highly significant (p < 0.05). The degree of oral hygiene was decidedly in relation to the most severe forms of gingival hyperplasia (grade 2-3), (p < 0.001). No relation was found for the duration of therapy, distribution of the DMF index and the level of drugs in the blood.
authors.affiliation: Istituto di Clinica Odontoiatrica, Università degli Studi, Parma.
authors.forename: P
authors.initials: P
authors.lastname: Vescovi
authors.forename: A
authors.initials: A
authors.lastname: Savi
authors.forename: G M
authors.initials: GM
authors.lastname: Macaluso
authors.forename: P U
authors.initials: PU
authors.lastname: Gennari
mesh_terms: D000293:Adolescent; D000328:Adult; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D016572:Cyclosporine / Q000009:adverse effects* / Q000097:blood; D004245:DMF Index; D004359:Drug Therapy, Combination; D005260:Female; D005886:Gingival Hypertrophy / Q000097:blood / Q000139:chemically induced* / Q000145:classification; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000097:blood; D016030:Kidney Transplantation; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use; D009909:Oral Health
chemical_list: D002121:Calcium Channel Blockers; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009543:Nifedipine